QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,656 signal articles · 530 in last 24h · 105,348 total before filter · latest 36m ago
530last 24h
2495last 7d
486● bullish (7d)
259● bearish (7d)
200publishers
AllMacro171Earnings1529M&A138Regulatory14Product8Analyst24
✕ clear all filtersticker: ^IXICsentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
Stock Futures Rise After Nvidia Earnings
Barrons.com77d agobearish
Stock Futures Rise After Nvidia Earnings

Stocks were on track to rise Thursday as investors digested strong results from artificial intelligence chip maker Nvidia and hoped for progress in the peace talks between the U.S. and Iran. The three major indexes snapped a three-session losing streak on Wednesday after President Donald Trump said the U.S. was in the final stage of negotiations with Iran to end the war in the Middle East. Moves early Thursday suggest that the market has concluded that Nvidia’s first-quarter earnings were good, but not good enough to keep the AI rally going.

Markets Falling After Tech Selloff. Nvidia Earnings in Focus.
Barrons.com79d agobearish
Markets Falling After Tech Selloff. Nvidia Earnings in Focus.

Markets were on course to open in the red Tuesday as the chip-stocks rally that has powered gains for much of the year continued to lose steam. Stock futures tied to the tech-heavy Nasdaq were down 0.3%, having finished 1.5% lower the previous session led lower by a Big Tech selloff. Dow Industrial futures were falling 34 points, or 0.1%, while S&P 500 futures dropped 0.2%.

Regeneron Stock Tumbles on Melanoma Drug-Trial Miss
The Wall Street Journal80d agobearish
Regeneron Stock Tumbles on Melanoma Drug-Trial Miss

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

Stock Futures Drop as Inflation Fears Grip Markets
Barrons.com80d agobearish
Stock Futures Drop as Inflation Fears Grip Markets

Stocks looked set to fall again on Monday as investors continued to worry about higher inflation, with the U.S. and Iran seemingly making no progress in their ongoing peace talks. The three major indexes tumbled on Friday, dragged down by soaring U.S. Treasury yields. The lack of a peace deal to end the conflict in the Middle East has caused investors to fret about a flare-up in inflation, with shipping through the Strait of Hormuz still disrupted.

Dynatrace Earnings Beat Estimates. The Software Stock Is Falling Anyway.
Barrons.com85d agobearish
Dynatrace Earnings Beat Estimates. The Software Stock Is Falling Anyway.

FEATURE Dynatrace stock was falling following the software company’s latest earnings report as an earnings beat failed to reverse an extensive slide in the stock price. Dynatrace which operates a cloud observability platform, posted fiscal fourth-quarter earnings of 41 cents a share, ahead of the 39 cents analysts had anticipated.

Nasdaq Drops as Chip Fever Breaks
Barrons.com85d agobearish
Nasdaq Drops as Chip Fever Breaks

Chip stocks got beat up after the latest inflation report. The tech-heavy Nasdaq was down 0.7%, the S&P 500 was down 0.2% while the Dow gained 56 points, or 0.1%. Notably, almost all major chip stocks were down, barring Nvidia.